Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.950
-0.040 (-1.34%)
At close: Sep 12, 2025, 4:00 PM EDT
2.950
0.00 (-0.01%)
After-hours: Sep 12, 2025, 7:32 PM EDT
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $62.47M in the quarter ending June 30, 2025, with 43.13% growth. This brings the company's revenue in the last twelve months to $203.73M, up 16.75% year-over-year. In the year 2024, Akebia Therapeutics had annual revenue of $160.18M, down -17.70%.
Revenue (ttm)
$203.73M
Revenue Growth
+16.75%
P/S Ratio
3.36
Revenue / Employee
$1,125,597
Employees
181
Market Cap
782.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AKBA News
- 8 days ago - Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection - Seeking Alpha
- 16 days ago - Akebia Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference - GlobeNewsWire